Dong Kook Lifescience said on the 2nd that last year's consolidation revenue was 130.3 billion won. Revenue fell 1% from a year earlier. Operating profit was 13.0 billion won, up 9% from a year earlier. Net profit was 8.7 billion won, up 286%.
Dong Kook Lifescience's contrast agent business unit posted 88.1 billion won in revenue last year. A contrast agent is a chemical substance that helps the subject stand out during X-ray or magnetic resonance imaging (MRI) scans. In addition, the MEMD (diagnostic equipment and medical devices) business unit recorded 42.2 billion won in revenue.
A Dong Kook Lifescience official said, "New contrast agent products have taken hold in the market, and we have expanded our business across healthcare, including medical devices and medical artificial intelligence (AI)," adding, "As interest expense decreased and operating income improved, net profit increased."